Journal of Pharmaceutical Innovation最新文献

{"title":"Tailoring Drug Release Kinetics in Lipophilic Drug-Loaded Oral Microemulsions: Impact of Surfactant Chain Length","authors":"Himanshu Paliwal,&nbsp;Bhupendra G. Prajapati,&nbsp;Akshay Parihar,&nbsp;Mohammad Rashid Khan,&nbsp;Chetan Singh Chauhan","doi":"10.1007/s12247-025-09952-z","DOIUrl":"10.1007/s12247-025-09952-z","url":null,"abstract":"<div><h3>Purpose</h3><p>The objective is to study the influence of surfactant chain lengths on the solubilization capacity and release pattern from the Rosuvastatin calcium-loaded microemulsion.</p><h3>Methods</h3><p>In the study, rosuvastatin calcium was incorporated into oil-in-water microemulsion formulations using surfactants of varying chain lengths. The developed formulations were then characterized for physicochemical properties, along with stability, release profile and in vitro intestinal permeability. The cytotoxicity assay was performed to assess the safety of microemulsion formulation.</p><h3>Results</h3><p>The stability of microemulsion formulation increases with the increase in carbon chain as indicated with smaller globule size, excellent dispersibility, and reduced dynamic surface tension. Furthermore, the stable rosuvastatin calcium-loaded microemulsion showed relatively higher transmittance value which was observed to be decreased with their dilution over time. The release study showed that the formulations with longer chain length surfactants exhibited higher rate of drug release in both SGF and SIF. The release kinetics of the developed formulation follow zero order equation and release mechanism was identified as supercase-II transport type diffusion. Additionally, the selected microemulsion system did not show any signs of cytotoxic potential on HCT-116 cells.</p><h3>Conclusions</h3><p>It can be concluded that the use of surfactant with longer chain length showed improvement in the transport of the drug through the lipid-rich membrane of intestine. The stable microemulsion allows regulation of epithelial cells and facilitating the paracellular transport of the drug.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143594678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review on the Treatment and Diagnosis of Systemic Lupus Erythematosus Using Nanoparticle Systems","authors":"Amin Seddigh,&nbsp;Zahra Salmasi,&nbsp;Fatemeh Kalalinia,&nbsp;Somayeh Marouzi,&nbsp;Maryam Hashemi","doi":"10.1007/s12247-025-09954-x","DOIUrl":"10.1007/s12247-025-09954-x","url":null,"abstract":"<div><p>Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease characterized by inflammation due to autoantibodies against nuclear antigens. Current treatments suffer from poor bioavailability, low specificity, and significant side effects. Nanoparticle (NP)-based drug delivery systems offer promising alternatives through enhancing solubility, stability, bioavailability, controlled release and targeted delivery of drugs. Recent studies have demonstrated that NPs with various structures provide a novel approach for treating SLE, potentially reducing side effects while improving efficacy of therapeutic agents. This review aims to present the current status of SLE therapy, along with the potential advantages and challenges of using NPs in diagnosis and treatment of SLE.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143602414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced Reepithelization and Dermal Regeneration of a Novel Pongamia Oil Combination Based Chloramphenicol-Coloaded Curcumin Nanoemulsion Fortified with a Chitosan Hydrogel: Statistical Optimization, ex vivo and in vivo Studies","authors":"Bhargav E,&nbsp;Gowtham A,&nbsp;Somasekhar Reddy K,&nbsp;Sudheer Akkiraju","doi":"10.1007/s12247-025-09943-0","DOIUrl":"10.1007/s12247-025-09943-0","url":null,"abstract":"<div><h3>Purpose</h3><p>In the present study, a novel pongamia oil combination-based chloramphenicol (CPL)-coloaded curcumin (CUR) nanoemulsion (NE)-fortified chitosan hydrogel was formulated for effective wound healing.</p><h3>Methods</h3><p>The nanoemulsion was optimized by a central composite design. The factors that exhibited a significant (ANOVA) effect on the responses were studied. FT-IR and DSC studies indicated the compatibility of the drugs with excipients. The selected independent variables were Pongamia oil (PO): Tween 80: propylene glycol (PG), stirring time (ST) and sonication time, and the dependent variables selected were globule size and PDI.</p><h3>Results</h3><p>The globule size of the formulations F15a &amp; F15b was found to be 280.23 ± 0.21 and 276.45 ± 0.29 nm, with PDIs of 0.390 ± 0.02 and 0.593 ± 0.02 and zeta potentials of -65.43 ± 0.39 and -70.73 ± 0.63 mV, which confirmed the uniform globule size distribution and stability of the formulations. Compared with the plain drugs, formulations F15a and F15b presented a greater zone of inhibition against <i>Staphylococcus aureus</i> (38 &amp; 35 mm) and <i>E. coli</i> (32&amp;29 mm). TEM analysis revealed a nearly spherical shape of the globules that was free from coalescence. The <i>invitro</i> drug release data indicated sustained drug release for up to 72 h. The <i>exvivo</i> drug release rates of F15a and F15b were 92.4% and 95%, respectively, for CPL and 87.6% and 94%, respectively, for CUR at 24th h. Contour plots were used to select the desired batch range. The stability studies indicated that the formulations remained stable at 40 ± 2 °C and an RH of 75 ± 5%. Compared with the control (70.00 ± 0.18%) and standard (92.04 ± 0.84%) groups, the optimized NE-CPL-CUR hydrogel F15a &amp; F15b-treated groups exhibited greater wound contraction (94.44 ± 0.56 &amp; 99.08 ± 0.18%) at the end of 21 days. Histopathological studies revealed better and improved reepithelization and epidermal and dermal regeneration.</p><h3>Conclusion</h3><p>The results of the present study demonstrated that the developed NE-CPL-CUR (0.5:1; CPL and CUR) chitosan-based hydrogel provided better wound healing because of the synergistic combination and presence of Pongamia oil in the nanoemulsion.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143594776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Machine Vision Technique for Analyzing the Blending Process of Sustained-Release Pellets","authors":"Sijun Wu,&nbsp;Guangpu Fang,&nbsp;Guoming Zhou,&nbsp;Xiaoyang Zhang,&nbsp;Fan Li,&nbsp;Zhanrui Zhang,&nbsp;Yongqiang Ma,&nbsp;Hai Liu,&nbsp;Wenlong Li","doi":"10.1007/s12247-025-09960-z","DOIUrl":"10.1007/s12247-025-09960-z","url":null,"abstract":"<div><h3>Objectives</h3><p>The tablet of multi-unit pellet system (TMUPS) tends to enable diversified therapeutic outcomes, due to the characteristic of containing pellets with different release behaviors. In the development of TMUPS formulations, it is essential to uniformly blend the pellets to ensure that the drug release profile of the formulation meets expectations.</p><h3>Methods</h3><p>In order to achieve the characterization of the blending status of sinomenine hydrochloride pellets and determine the blending endpoint, a method based on the machine vision (MV) technique combined with the independent circle (IC) image analysis algorithm was proposed. Fifteen experimental batches of the blending process with varying conditions were designed for the research. The images of pellets distribution at six different layers were captured using a MV photography platform, and the spatial distribution of the pellets during the blending process was digitally characterized using the IC algorithm.</p><h3>Results</h3><p>Compared to the traditional counting method, the utilization of the MV technique allowed for the accurate and timely determination of the blending endpoints of all batches and enabled the monitoring of changes in the blending status to detect when the demixing phenomenon occurred, based on the proportions, total number, and area occupied by the two types of pellets.</p><h3>Conclusions</h3><p>The MV method established in this paper may serve as a potential strategy for the monitoring of the relatively complex blending process involving multiple types of pellets with similar properties.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143583506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Ketoconazole-Loaded Niosomal Gel with Carbamide for Enhanced Topical Delivery and Skin Hydration in Fungal Infections","authors":"Prajitha Biju,&nbsp;Manjunath M. Shenoy,&nbsp;Rouchelle Tellis,&nbsp;Ramesh Bhat,&nbsp;Ranajit Das,&nbsp;Ashwini Prabhu,&nbsp;Mohammed Gulzar Ahmed,&nbsp;Vivek Ghate","doi":"10.1007/s12247-024-09916-9","DOIUrl":"10.1007/s12247-024-09916-9","url":null,"abstract":"<div><h3>Purpose</h3><p>Atopic dermatitis is a condition, wherein the outermost skin layer is disrupted, leading to excessive water loss and cutaneous lesions. This study assesses an antifungal topical formulation utilizing a vesicular system loaded with ketoconazole and a hydrating agent to treat fungal skin infections while preventing resistance and recurrence.</p><h3>Methods</h3><p>The Central Composite Design in Design Expert software was used to optimize ketoconazole-loaded niosomes, with vesicle size and drug entrapment efficiency as dependent variables and surfactant and organic solvent concentrations as independent variables. The optimized formulation was evaluated against predicted values, and compatibility and stability were analyzed via FT-IR and differential scanning calorimetry. Niosome morphology was examined using light microscopy and SEM. Niosomes were incorporated into a hydrogel containing 5% carbamide, a pH stabilizer, and preservative to enhance dermal bioavailability. The gel underwent evaluations for viscosity, antifungal activity, <i>in vitro</i> drug release, <i>ex vivo</i> permeation, skin irritation, TEWL, and histopathology.</p><h3>Results</h3><p>Optimized niosomes had a vesicle size of 275 nm and 98.38% drug entrapment efficiency. The gel was translucent, non-sticky, had a viscosity of 18,200 mPa·s at 20 °C, and exhibited a sustained <i>in vitro</i> drug release. The release kinetics followed zero-order and Baker-Lonsdale models, with R² values of 0.94 and 0.99. Application on mice reduced moisture loss and improved skin barrier function.</p><h3>Conclusion</h3><p>The ketoconazole-loaded niosomal gel is a promising carrier for dermal drug delivery against fungal infections.</p><h3>Graphical Abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143594778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioinspired Chitosan-Based Patches Enriched With Lipid-Casein Nanocarriers: An Innovative Approach for Wound Management and Evaluation in a Rat Model","authors":"Madhu Kumari,&nbsp;Monika Dwivedi,&nbsp;K. Jayaram Kumar,&nbsp;Ashok Kumar Pattnaik","doi":"10.1007/s12247-025-09946-x","DOIUrl":"10.1007/s12247-025-09946-x","url":null,"abstract":"<div><h3>Purpose</h3><p>Wounds are physical injuries that disrupt the skin’s structure and function, necessitating a complex healing process to restore integrity and functionality. Ursolic acid (UA), a naturally occurring compound, exhibits remarkable antioxidant, anti-inflammatory, and antimicrobial properties, making it a promising candidate for wound healing applications. However, its therapeutic potential is hindered by challenges such as poor solubility, limited permeability, and low bioavailability, which restrict its effectiveness in clinical settings. Delivering UA through nanocarriers provides a significant advantage in resolving these issues, we designed bioinspired milk protein casein-lipid nanocarriers (UA LCNPs) that were incorporated in a chitosan-based transdermal patch.</p><h3>Method</h3><p>UA LCNPs were prepared using the desolvation method utilizing casein and Phospholipon 90 ^® G. UA LCNPs were characterized by dynamic light scattering (DLS), surface morphology, DSC, and FTIR parameters. The formulated nanoparticles were then incorporated into the chitosan patch using solvent-casting method. The UA LCNPs loaded patches were evaluated for the drug content, surface pH, FESEM, swelling index, hemolysis assay, antioxidant, etc. Furthermore, the developed transdermal patch was characterized and evaluated for in vitro permeation and in vivo wound treatment activity in rats.</p><h3>Results</h3><p>The formulated nanoparticles were spherical, with particle size (PS) 172.9 nm, zeta potential (ZP) -14.5 mV, and a PDI value were 0.336. The prepared patch from the nanoparticles was smooth, homogenous, and flexible having high drug content. The results showed that a transdermal patch can effectively control the UA release from the patch and the accumulation of UA in the skin. The hemolysis data provides insight into safety profile and <i>invivo</i> antioxidant activity showing strong antioxidant properties by inhibiting lipid peroxidation. The results showed that the transdermal patch UA LCNPs (test group) demonstrated effective wound healing compared to the control group and marketed ointment groups.</p><h3>Conclusion</h3><p>This work serves as a platform for the strategic management of wounds through phytomolecules shelled in casein nanocarriers subduing associated solubility and permeability hurdles. Moreover, accommodating them in patches for self-administration at the injury site presents an effective mode of wound management.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div><div><p>Graphical representation of delivery of bioinspired hybrid nanocarriers UA LCNPs through a transdermal patch on excision wound model displaying fast healing</p></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143564415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Good Laboratory Practice in Preclinical Research: Lessons Learned from Warning Letters Issued Between 2019 and 2024 Addressing Violations to the 21 Code of Federal Regulation Part 58","authors":"Isra Dmour","doi":"10.1007/s12247-025-09932-3","DOIUrl":"10.1007/s12247-025-09932-3","url":null,"abstract":"<div><h3>Purpose</h3><p>The study aims to critically review US FDA warning letters (WLs) issued during inspections between 2019 and 2024 for compliance with Good Laboratory Practice in Preclinical research facilities.</p><h3>Methods</h3><p>WLs were downloaded from the US FDA public domain of the WLs and the content of each WL was assessed based on types and frequencies of violations and corrective and preventive actions (CAPA) employed by the testing facility or requested by the FDA investigators. Each WL was evaluated and critically analyzed about the applicable regulation. Violations were correlated with consequences of non-compliance, as addressed by the FDA inspectors.</p><h3>Results</h3><p>Eight WLs letters were analyzed. The incidence of violations concerning the QAU’s failure to meet responsibilities, documentation deficiencies, noncompliance with study protocols, deviations in animal handling, and data capture in the final study report was 12% each. The violations concerning the study director’s failure to fulfil his/her duties and deficient/ noncompliance to pertinent SOPs were 10% each. The incidence of inadequate qualifications among study personnel and the management of specimens/reagents and controls was 9% and 6%, respectively. The minimal variance was linked to specimen/record retention (5%).</p><h3>Conclusion</h3><p>Testing facilities in preclinical research are requested to evaluate personnel responsibilities, improve GLP training programs, and implement adequate standard procedures to comply with GLP standards, reducing the recurrence of these violations and enhancing data integrity and validity that will support a clinical submission.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143564507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on Effective Phase Resolution of Xiaoyao Powder and its Anti-Mammary Hyperplasia Effect","authors":"Dai Xiaofang,&nbsp;Zhu Meiwei,&nbsp;Yan Lili,&nbsp;Yang Fangfang,&nbsp;Yang Han,&nbsp;Wang Rui,&nbsp;Guan Qingxia","doi":"10.1007/s12247-025-09937-y","DOIUrl":"10.1007/s12247-025-09937-y","url":null,"abstract":"<div><h3>Purpose</h3><p>Xiaoyao San (XYS) is an ancient clinical dosage form in China. Our previous research discovered that the compound decoction of traditional Chinese medicine presents a mixed-phase system, encompassing nanophase, precipitated phase, suspension phase, and true solution phase. Hence, this study is intended to screen out the effective phases among the four phases of XYS and explore its anti-hyperplasia effect on mammary glands.</p><h3>Methods</h3><p>Four phases of XYS were prepared by centrifugation-dialysis. The preparation process, characterization, determination of chemical composition, and anti-breast hyperplasia effects were investigated.</p><h3>Results</h3><p>The four phases of XYS were successfully separated. The characterization results indicated that the nanophase of XYS had the smallest particle size, polydispersity index (PDI) value, and the largest potential value, with an average particle size of approximately 100 nm. In the content determination, the component content ratios of the four phases were consistent, and the content of the nanophase was much higher than that of the other phases. The pharmacodynamic results demonstrated that all indicators of rats in the XYS whole liquid and nanophase groups were significantly improved compared with those in the model group (<i>p</i> &lt; 0.05). At the same time, there were no significant differences in the indicators of rats in the other phase groups. The grey correlation degree analysis revealed that the common peaks of both XYS whole liquid and nanophase were correlated with the pharmacological effect, and the correlation degrees were all greater than 0.7.</p><h3>Conclusion</h3><p>This research successfully proved from physicochemical characterization and pharmacodynamics perspectives that the nanophase is the effective phase and that multiple components jointly exert the anti-hyperplasia effect of mammary glands.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143564416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Optimization of a Self-Nanoemulsifying Drug Delivery System (SNEDDS) for Enhanced Oral Delivery of Dolutegravir","authors":"Raghuveer Pathuri,&nbsp;Lakshmi Devi Gottemukkula","doi":"10.1007/s12247-025-09951-0","DOIUrl":"10.1007/s12247-025-09951-0","url":null,"abstract":"<div><h3>Purpose</h3><p>The aim of this present study is to develop and optimise a self-nano emulsifying drug delivery system (SNEDDS) for the enhanced oral delivery of dolutegravir (DTG), a poorly water-soluble antiretroviral drug.</p><h3>Methods</h3><p>The SNEDDS formulation was developed using Capmul MCM (oil), Kolliphor RH40 (surfactant), and PEG 400 (co-surfactant). Box Behnken design was employed to optimize the composition of the SNEDDS formulation. The prepared formulations were evaluated for droplet size, polydispersity index (PDI), zeta potential, self-emulsification time, and in vitro drug release.</p><h3>Results</h3><p>The optimized SNEDDS formulation (F2) exhibited a droplet size of 79.2 ± 0.9 nm, PDI of 0.105 ± 0.012, zeta potential of -32.1 ± 1.5 mV, and self-emulsification time of 22 ± 2 s. In vitro drug release studies demonstrated a significantly higher cumulative drug release from the optimised SNEDDS formulation (98.9 ± 0.9% in 60 min) than pure DTG (42.5 ± 2.1%). The optimized formulation exhibited excellent thermodynamic stability and robustness under various stress conditions. Ex vivo drug release studies using rat stomach tissue confirmed the enhanced drug release potential of the optimized SNEDDS formulation in the gastric environment.</p><h3>Conclusion</h3><p>The developed SNEDDS formulation offers a promising approach for the enhanced oral delivery of DTG, potentially improving its bioavailability and therapeutic efficacy.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143564414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence: Preface, Applications and Future Perspective in Relation to Pharmaceutical Sector","authors":"Supriya Singh,&nbsp;Sanket Kumar,&nbsp;Sheikh Shahnawaz Quadir,&nbsp;Saloni Bhandari,&nbsp;Bhuvanesh Baniya,&nbsp;Garima Joshi,&nbsp;C. P. Jain,&nbsp;Deepak Choudhary","doi":"10.1007/s12247-025-09940-3","DOIUrl":"10.1007/s12247-025-09940-3","url":null,"abstract":"<div><h3>Purpose</h3><p>Artificial intelligence (AI) platforms are among the most prominent digital innovations in the contemporary time. The colossal growth and success of AI has garnered the attention of the scientific community and it is also being accepted in the public domain. The current review aims to provide in depth information about the utilization of AI in the pharmaceutical sector along with the limitations, ethical-legal aspects and future perspective of this technology in uplifting the growth of this sector. </p><h3>Methods</h3><p>The accredited web pages of PubMed, Google Scholar, Scopus and Web of Science were accessed using the terms “artificial intelligence” and “pharmaceutical”. Cross-referencing important articles yielded additional references which were evaluated and utilized for inclusion in writing this review.</p><h3>Result</h3><p>The dexterity of AI tools was explored in numerous domains of pharmaceutical sector like drug discovery, pharmaceutical product development, manufacturing, product management, clinical &amp; diagnostic field, 3D printing technology and community pharmacy. It was found that the augmentation of AI with pharmaceutical sector will lift the growth of this sector by heaps and bounds for the reason that every facet will be reshaped in terms of finances and time.</p><h3>Conclusion</h3><p>Significant developments in AI offers a revolutionary chance for drug discovery, formulation, clinical and diagnostic applications, 3D printing and plentiful applications in the pharmaceutical industry. However, AI presents risk factors and ethical concerns that must be handled before society, health systems, and individuals can fully benefit from it. Pharmaceutical developers should ensure that the AI tools and procedures comply with all ethical and regulatory standards enforced by the regulatory agencies.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143564489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}